These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 35721798)
1. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management. Dipasquale V; Cucinotta U; Romano C Biologics; 2022; 16():57-66. PubMed ID: 35721798 [TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
3. The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics. Limdi JK; Farraye FA Crohns Colitis 360; 2021 Jul; 3(3):otab015. PubMed ID: 36776664 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related]
5. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Dipasquale V; Cicala G; Spina E; Romano C Front Pharmacol; 2022; 13():846151. PubMed ID: 35370732 [No Abstract] [Full Text] [Related]
6. Progress with infliximab biosimilars for inflammatory bowel disease. Kurti Z; Gonczi L; Lakatos PL Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797 [TBL] [Abstract][Full Text] [Related]
7. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385 [TBL] [Abstract][Full Text] [Related]
9. Biosimilars in ulcerative colitis: When and for who? Ilias A; Gonczi L; Kurti Z; Lakatos PL Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937 [TBL] [Abstract][Full Text] [Related]
10. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687 [TBL] [Abstract][Full Text] [Related]
17. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Avila-Ribeiro P; Fiorino G; Danese S Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114 [TBL] [Abstract][Full Text] [Related]
18. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Danese S; Fiorino G Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565 [TBL] [Abstract][Full Text] [Related]
19. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. Najeeb H; Yasmin F; Surani S World J Clin Cases; 2022 May; 10(14):4327-4333. PubMed ID: 35663066 [TBL] [Abstract][Full Text] [Related]
20. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System? Gonczi L; Ilias A; Kurti Z; Lakatos PL Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]